Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Boehringer Ingelheim's Jascayd (nerandomilast) gains MHRA approval for idiopathic and progressive pulmonary fibrosis after Ph3 success
Small molecule, pulmonary, PDE4B inhibitor, idiopathic pulmonary fibrosis, antifibrotic - Read more

HanchorBio, InxMed partner on preclinical combination studies evaluating HCB101 with FAK inhibitor and FAP-targeted ADC
Research collaboration, oncology, antibody, small molecule, drug discovery - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Keenova Therapeutics' Xiaflex (collagenase clostridium histolyticum) succeeds in Ph3 trial for plantar fibromatosis
Protein therapy, musculoskeletal, enzyme injection, plantar fibromatosis, collagen targeting - Read more

Ipsen's Dysport (abobotulinumtoxinA) meets Ph3 goals in both episodic and chronic migraine trials
Protein therapy, neurological, botulinum toxin, migraine, prophylactic treatment - Read more

Fate Therapeutics' FT819 (anti-CD19 CAR-T) shows early Ph1 promise in treatment-resistant systemic sclerosis
Cell therapy, autoimmune, CAR-T, systemic sclerosis, anti-CD19, off-the-shelf - Read more

Seres Therapeutics reports Ph1 SER-155 (microbiome therapy) data showing 80% response rate in immune checkpoint inhibitor-related enterocolitis
Microbiome therapy, cancer, immune checkpoint inhibitor, enterocolitis, gastrointestinal inflammation - Read more

MindRank raises $52M Series B, advancing AI-discovered oral GLP-1 obesity pill to Phase III
AI/ML platform, obesity, small molecule, GLP-1, clinical-stage - Read more

Alchemab Therapeutics raises $34M Series A extension from British Business Bank, advancing AI-enabled antibody pipeline
Clinical-stage, antibody, AI/ML platform, neurological, rare disease - Read more

Allotera Therapeutics closes $35M financing to advance off-the-shelf CAR-T therapies for T-cell cancers
Cell therapy, oncology, CAR-T, allogeneic, clinical-stage, hematological malignancies - Read more

Genesys University Seed Fund holds $30M first close, targeting early-stage life sciences startups
Life sciences, venture capital, early-stage, biotechnology - Read more

HHS drafts COVID vaccine injury compensation table under RFK Jr.'s leadership
mRNA vaccine, infectious disease, regulatory, operational - Read more

Saol Therapeutics resubmits SL1009 (DCA) to FDA for pyruvate dehydrogenase complex deficiency with new survival data
Small molecule, neurological, metabolic, pyruvate dehydrogenase complex deficiency, mitochondrial disease, rare disease - Read more

AstraZeneca, Daiichi Sankyo near UK price deal for Enhertu breast cancer drug NHS access
Antibody-drug conjugate, breast cancer, regulatory, pricing - Read more

Sanofi offers EU concessions to halt probe over misleading flu vaccine campaign against CSL Seqirus
Vaccine, infectious disease, regulatory, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

GSK terminates Alector neurodegenerative partnership after dual Phase 2/3 clinical failures
Partnership termination, neurological, antibody, milestone payments - Read more

AstraZeneca, Ionis Pharmaceuticals' Wainua (eplontersen) fails Ph3 trial for transthyretin-mediated amyloid cardiomyopathy
Antisense oligonucleotide, cardiovascular, small molecule, transthyretin amyloid cardiomyopathy, TTR silencer, phase 3 trial failure - Read more

FDA pauses release of complete response letters amid pharma petition challenging proprietary information disclosures
Regulatory policy, multi-disease, operational, strategic - Read more

FDA issues untitled letter to Lundbeck over misleading efficacy claims for migraine drug Vyepti
Monoclonal antibody, migraine, regulatory, competitive - Read more

Dr. Reddy's halts generic semaglutide supply after discovering active pharmaceutical ingredient specification issues
Small molecule, metabolic disease, operational, competitive - Read more

FDA issues warning letter to Amphastar Pharmaceuticals subsidiary over GMP violations at California facility
Manufacturing compliance, GMP violation, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here